

FOR

HEALTH

HEALTH

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

Stock



## Our Vision

Our vision is to be the most innovative and  
ambitious organization in the world.  
We will achieve this by being the most  
ambitious organization in the world.

## Our Mission

Our mission is to be the most innovative and  
ambitious organization in the world.

# Contents

2	C	a	.	ma	
4		a	a		
		a	a	m	D
				a	A a
3		s	a		D
41	.	m	C		C
42	.	m	C		C
43	.	m	C		C
4	.	m	C		C
4	.	m	C		C
4	\			m	C
				C	a
				a	a
				s	a
				m	

## Directors

- ▼▼ . C (陳啟宇) ( n )
- ▼▼ . a a (姚方) ( - n )
- ▼▼ . a (吳以芳) ( n )

### Executive Directors

- ▼▼ . a a (徐曉亮)
- ▼▼ . (龔平)<sup>1</sup>
- ▼▼ . a D (潘東輝)<sup>1</sup>
- ▼▼ . a a (梁劍峰)<sup>2</sup>
- ▼▼ . a Ca (王燦)<sup>3</sup>
- ▼▼▼▼ . a (沐海寧)<sup>5</sup>

### Independent Non-Executive Directors

- ▼▼ . a a (江憲)

## Stock Abbreviation

AS A

## Share Listing

AS : S a a S a

S C : 600196

S a : S a m

S C : 02196

## A Share Registrar and Transfer Office in the PRC

C a S D & C a C a m (CS DCC)

S a a B a

C a. a B

166 a a a

✓ D

S a a, C a

## H Share Registrar and Transfer Office in Hong Kong

. S m

54, C

183 a a

## Company's Website

// a ma. m

<sup>1</sup> A 30 2020

<sup>2</sup> 17 a a 2020

<sup>3</sup> 21 a a 2020

<sup>4</sup> A 21 a a 2020

<sup>5</sup> 30 2020

<sup>6</sup> A 30 a 2020



## FINANCIAL REVIEW

D 2019. 0.85% ▼▼ B13,965 m  
 ▼▼ B2,302 m ▼▼ B1,715 m 4.83% a 13.10%,  
 ( / ), (Ba ) ( C ) (2,000 ), ▼▼ B224 m ▼▼ B100 m ; a (3)  
 ; (2) ; (4) B a a s am ▼▼ a.  
 D 2019. 13.56% ▼▼ B0.67 a m a

## REVENUE

D 2019. 0.85% ▼▼ B13,965 m a m a  
 m a m m C ▼▼ a a am ▼▼ B9,894 m a a ▼▼ B4,071  
 a a 7.97% a m a &D m a m ▼▼ B9,952 m ,  
 2019. m a m am





## DEBT STRUCTURE, LIQUIDITY AND SOURCES OF FUNDS

### Total Debts

A a 30 2020, a a ▼▼ B23,358 m m ▼▼ B21,137 m a a 31 D m 2019 ma

# Management

Discussion and Analysis

## Maturity Structure of Outstanding Debts

	30 June 2020	31 December 2019
1 year or less	12,405	8,560
1 to 2 years	7,834	6,860
2 to 5 years	2,633	5,396
5 years or more	483	321
<b>Total</b>	<b>23,358</b>	<b>21,137</b>

## Available Facilities

As at 30 June 2020, the Group has available facilities of R9,750 million, compared to R32,709 million as at 31 December 2019. The decrease is primarily due to the expiry of R23,000 million of facilities. As at 30 June 2020, the Group has available facilities of R48,320 million, compared to R15,611 million as at 31 December 2019. The increase is primarily due to the expiry of R32,709 million of facilities.

## Collateral and Pledged Assets

As at 30 June 2020, the Group has collateral of R217 million (31 December 2019: R217 million), compared to R217 million (31 December 2019: R217 million). As at 30 June 2020, the Group has pledged assets of R396 million (31 December 2019: R303 million), compared to R396 million (31 December 2019: R303 million). The increase is primarily due to the expiry of R303 million of pledged assets.

## Cash Flow

The Group's cash flow is primarily generated from its operating activities. The Group's cash flow is primarily generated from its operating activities. The Group's cash flow is primarily generated from its operating activities.

	January – June 2020	January – June 2019
Operating activities	1,461	1,450
Investing activities	(2,379)	(1,079)
Financing activities	827	(496)
Net change in cash and cash equivalents	(81)	(125)
Cash and cash equivalents at the beginning of the period	8,284	7,175
Cash and cash equivalents at the end of the period	8,177	7,052





Pharmaceutical manufacturing and R&D  
 2019. 7.97%  
 2019. 7.40% 9.54%  
 2019. 15.4%  
 2019. 46.27%  
 2019. 10.6%

COVID-19  
 2020.  
 61.9%, 109.6% 244.5%,  
 (2,000),  
 B224 m  
 B100

Jan - Jun 2020

	Jan - Jun 2020	2019	am a (%)
1: a m a a 2020 a a am a	1,767	1,807	2.19
2: a - m a a a ( 3)	422	264	59.94
3: a - a a a ( 4)	1,800	2,331	22.77
4: a a m a a a ( 5)	755	1,224	38.35
5: a a a m a a a ( 6)	1,248	1,140	9.49
6: a m a a a ( 7)	247	419	41.03
7: A a m a ( )	452	675	32.97

1: a m a a 2020 a a am a  
 2: a m a a m a m a a a m a a ( ), a (A m a a ), a m a a a a , m a m a (C ) (Ba ), m a ( a s ), m a a a ( ), a ( a a ), a a a a ( ) a a m a  
 3: a - m a a a m a a a ( a a ), a a ( s ), a am ( a a ), a , a a , m m ( ), a a a a a  
 4: a - a a a m a m a a a a a , m a m ( C a a C m a ), a a ( ) m a ( - ), a m m a a a ( s a D a ), m m ( s ), a m a am m ( a s ), am , a - m , a - m a a a am m ( a s ), a m , a m ( a D ), m m ( B ), a m a ( a s ) a



A a , ma &D m a m a m a :

No.	Name of R&D project on drugs (products)	R&D stages as at the end of the Reporting Period in the PRC		R&D stages as at the end of the Reporting Period in other countries	
		R&D stage	Stage of clinical trial	R&D stage	Stage of clinical trial
1	SA-189 (Ca)	C	a a	a a	a a (U.S.)
2	GA-411	C	a a		
3	VA-1501	C	a a	C	a a (U.S.)
4	GA-437	C	a a	C	a a (U.S.)
5	a a a	C	a a		
6	GA-159	C	a a		
7	VA-1001 (1)	C	a a	C	a a (U.S.)
8	D a m	C	a a		
9	GA-647 Ca	A	a a		
10	GA-207 a	A	a a		
11	GA-011 Ca	A	a a		
12	GA-338 a (2)	A	a a	A	a a (U.S.)

1: S a a a D m am U.S. DA;

2: A a a , a a a a C a a .

A a , &D m a a :

No.	Type	Name of R&D project on drugs (products)	R&D stages in China as at the end of the Reporting Period		R&D stages in other countries as at the end of the Reporting Period	
			R&D stage	Stage of clinical trial	R&D stage	Stage of clinical trial
1	B m a	ma	A			
2	B m a	a ma (2)	U.S.	a a	U.S.	a a
3	B m a	A a m ma S	U.S.	a a m		
4	B m a	m a A - ma	C	a a	a a (3)	
5	B m a	m a A - ma / C m a A	A	a a		

# Management

D a A a

No.	Type	Name of R&D project on drugs (products)	R&D stages in China as at the end of the Reporting Period		R&D stages in other countries as at the end of the Reporting Period	
			R&D stage	Stage of clinical trial	R&D stage	Stage of clinical trial
6	B	m a A - 2 D ma ... ma ▼▼ a A	A		a a	
7	B	m a A - 2 D ma ... ma ▼▼ a A	C	a a	➤ a	
8	B	m a ma A -C A-4 a A	A		a a	
9	B	m a ma A - A a A	A		a a	
10	B	m a ma / A -CD20 ▼▼ a A	C	m	➤ a ... ( 4)	
11	B	m a A - ma a A	A		a a	
12	B	m a A - 2 ma a A ( 5)	C	a a	➤ a	A
13	B	m a A - ma a A ( 6)	C	a a	➤ a /	A
14	B	m a ma A →D-1 a A ( 7)	C	a a	➤ a	A
15	B	m a ma A →D- 1 a A	A		a a	C a a ➤ a ( )
16	B	22 ▼▼ a A	C	a a	➤ a	
17	B	55 ▼▼ a A	C	a a	➤ a	
18	B	56 ▼▼ a A	A		a a	
19	C	m a ma A →D-1 ▼▼ a A a m a ma A - ma ▼▼ a A	C	a a	➤ a ... ( 10)	



No.	Type	Name of R&D project on drugs (products)	R&D stages in China as at the end of the Reporting Period		R&D stages in other countries as at the end of the Reporting Period	
			R&D stage	Stage of clinical trial	R&D stage	Stage of clinical trial
20	C m a a m	C m m a ma A →D-1 a m a A - ma a A	A			
21	C m a a m	C m m a ma A →D-1 (C a +5) a a - a m a A a a a a a s am C Ca ma	C a a	→ a ...		
22	C m a a m	C m m a ma A →D-1 (Ca a - ) a a a m a a - a s ma C Ca	C a a	→ a ...	C a a	→ a ...
23	C m a a m	C m m a ma A →D-1 C m a a a a -/ A a a m a Ca	C a a	→ a ...		
24	C m a a m	C m m a ma A →D-1 (Ca a -A m - ) a a a ) a a - a m a A a a a s am - ma C Ca	C a a	→ a ...	C a a	→ a ...
25	C m a a m	C m m a ma A →D-1 A m - a a a a a m A a C a Ca A a - C m a	C a a	→ a ...		

1: . A 2020, m a a a a a 2,000 a a a , 2,000 m  
a a a a 500m /50m/ ma ( a a ) a A... 2020,  
m a a a a ma ( a a ) a A.

2: S a a a mm a ... a a a , a a → a a  
→ . D a a , s a a B a ma a , a C m a , C a a  
C m a a a C a ma a , a a a a ma a ma a  
a , s a a , a a a (Ds) a (D-)  
a ma . A a a , 02 ( a ma , a am : a ; a am C a a :  
汉曲优) a a a C a a .

# Management

D a A a

3: ✓ a ... a m a a a a a m .

4: S ma a a a a a a ... a a C ✓ a a .

5: A a a a a a a a a C a; m , a a a a a a  
 ✓ A a U.S. DA a a

6: A a a a a a a C ✓ a a ; m , a a a a a a U.S.  
 DA a a

7: A a a a a a m a a a C a; a a a a a a a  
 m a a m a a a - m m a a a a a a a a a C  
 ✓ a a ; a a a a a B a a a a C a.

: A a a a a A a a.

: S a a a a a C a.

10: a a m m a ma a →D-1 m a a a m a a - ma  
 m a a a m a a a a a C ✓ a a a a a a a a a  
 m a a am - ma a , a a a a a m a a a a ma a a  
 a a am m .

A a , ma &D a :

No.	Type	Name of R&D project on drugs (products)	Indications	R&D stages as at the end of the Reporting Period in the PRC	Stage of clinical trial as at the end of the Reporting Period in the PRC
1	C m a	✓A-824	a m a a - a ( D - B) m a ( D - B) a a a m /	C a a	✓ a .
2	C m a	A a m a a a a a	m a a a m m a m a a a a a C m m m a ( 1)	C a a A a a	✓ a ...
3	C m a	a a a	. a m a a ma - a a a a a	✓ a a ✓ a a	✓ a . ✓ a ...
4	C m a	B m a	. m a ma a	✓ a a	✓ a .
5	C m a	a a	✓ a m	C a a	✓ a .
6	C m a	a a	. a a	✓ a a	✓ a ...

No.	Type	Name of R&D project on drugs (products)	Indications	R&D stages as at the end of the Reporting Period in the PRC	Stage of clinical trial as at the end of the Reporting Period in the PRC
7	C m a	a a	ma a a	D	
8	a	002	a a	A a	
			a	a a	
			a	A a	
			a a	a a	
			a	a	
9	a	C D-19 m A a (B a 162 1)( 2)	C .D-19		
	1:	A a a	a a a m a m a a	a m	a a a
		A;			
	2:	A a a , C D-19 m A a (B a 162 1) a a a a m	A	A	a a C a a , a
		a m m a a .			
		a a a m a a a m a m			, a a
		a a a m m .			a a m a a
		m a a a m a m .			a a a m a m a
		a m a m a a a			a m &D, a , a m
		a m a a ,			a a , a a
		a a a .			a a m a
		a m m a a a			a a m a
	( S)	a , m m a a a a (CA A) a a .D			, - - a
		a a a m m a m a			a a a a
		a a a m m a m m			a , m a m a m , a
		a a D A m a a a			m a m a m m , m
		a a a m a a			a , a , a m m a a a
		a a m			a a a
		a a			a a a m a a a
		a a a a a a			a a a a a a a a a a a a a a
		a a a a a a			a a a a a a a a a a a a a a
		a a a a a a			a a a a a a a a a a a a a a
		a a a a a a			a a a a a a a a a a a a a a
		a a a a a a			a a a a a a a a a a a a a a
		a a a a a a			a a a a a a a a a a a a a a
		a a a a a a			a a a a a a a a a a a a a a
		a a a a a a			a a a a a a a a a a a a a a
		a a a a a a			a a a a a a a a a a a a a a
		a a a a a a			a a a a a a a a a a a a a a

# Management

D a A a

D ... m a a ma m, a  
 a m ma m a a , a a a ... a m a m a ma a  
 ma am ma a a ma , a a a m ma . A  
 a a m a ma a m a ma am a 5,800 , a a ma a  
 a m a ma am a 1,000 ... m m ma , ma a a  
 - m a, ma m a, a a a ma a m , a -  
 ma a m a a am , a a a a ma a m m a a ; a  
 a m a a a ma a ma , a a ma ; a a , ma  
 a a m ma a m , a a a ma ; a ,  
 a a a \$ a m, a , a a a a \$ a m'  
 ma , a ma a a a am a am m a a -  
 a a - a - a a a A a, a m a m  
 a m A a ma ; a am m , ma a m L.S. a , m -  
 ma a m a a a ma a ma , a a ' a ma a a a a  
 ma .

D ... B2,639 m m m a a m a a m ,  
 a a 47.18% a m a 2019; m am B510 m ,  
 a 74.69% a m a 2019; m am B434 m ,  
 a 88.22% a m a 2019. - - a a  
 ma a a a m a - a m , a a 2019- C , a  
 am a a a , a a a m a a a ma . a a  
 m a a m Da a a m \$ a - , a , a  
 a ... a 2020, 30 Da a m a , a a ma 18,500 a  
 a m C a a a , a - - a .

D ... 2019- C ( C )  
 a a m a a m A a a a a m a ( - a a ).  
 a 2019- C a a a a a a a a , L.S.,  
 L.S. A a a . a a , m 2019- C a a am m  
 a B500 m ... a , m am C D-19 a m , a  
 ma a a a a m , a a a  
 am a , a a a a a a , a  
 a C a , - m a m a a a .

D ... \$ am a a a a a C D-19  
 a m am m a m ... a 2020, \$ am a am L.S. \$72  
 m a am L.S. \$6 m ( a a a a m \$ am a ), a  
 a - - a . m a a a a a , \$ am a  
 ma ( a m ma ), , a a , a &D m ma  
 a a m ma a a a a a . a  
 a 2020, am D ma C a , a m a ma ( Am a a ) a a  
 m ma .

a 2020, ' - a ma m m m a a a  
 a ma a a a a a . a a a 44 a a  
 a a a a a a m a , a a m a  
 , m - , a ma . ( a a ) a  
 a a .

a a a S4  
 D a a C .D-19 a m , m a a a m a m a  
 a m a 2019. m a a m a m  
 ▼▼ B1,359 m a a a 6.85% a m a 2019;  
 a a a a a m a a a a m  
 a a a ▼▼ B31 m a a 81.43% a m a 2019, a m  
 a a ▼▼ B2 m a a 98.40% a m a 2019.  
 a m C a a a a m m a a a m a ,  
 a a a m 3 a 4 , a a  
 a 37.8% a m a a a .

D a a a m a a a a m a a a a a a  
 a a a a a a a a a a a m a a a a  
 a a a a a a a a a a a a a a a  
 D a a a a m a a a a a a a a a a  
 a m C a a a , a , S a a / S a Ca a , a a a , a  
 a , m a , a a a , a C a a , a 'a a a a a a a a a ,  
 a a a 4,328 a a a a .

D a a a a m a a a a a a a a a a a m a m  
 m a a m m a , a a a m a a a a a a a , S , m ,  
 a m m a m m . a a a m a a a  
 m a m m , m a a m , m a a m a m . a

A a - m a a a a a a a a a a a a  
 m a a . B a a a a a a a a a 11 m a a  
 a a , m a a a a m a a a a a a a a  
 a a , A a m m , 2 a a a a a a a a a a  
 a a . D a a a a a a a a a , S a Ca a a m a a  
 a a a a a a a a a a a a a a a a a  
 m a 5 Ca a a a a 3 Ca a a m a a a a a  
 a a a a a a a a S C a a a a a a a a  
 a a a m m m a . C a a a S a a a a a a  
 , a a a a a a m a a a a a a

a m  
 a a a a a a a a a a a a  
 m a a a , ▼▼ B203,765 m a a - - a 1.04% a  
 a a a , ▼▼ B4,803 m a a a a ▼▼ B2,896 m ,  
 a - - a 3.32% a 2.67% a m a a a ,  
 a m a a m a a a .  
 a m a a a , S a m a m a a a a a a ,  
 a a m m a a , a m a a m a a a a  
 a m a a a a a a a a a a a a a  
 2020, S a m ' m a m a a a 4.38% - - ▼▼ B157,495 m .

# Management

D a A a

... a a ma , a \$ a m 30 , m a a a m a a  
 ... a m a a ma a 7,047, a a a  
 a 2020, \$ a m' a m a a ma a a a , a ▼ B11,016 m  
 a a 24.59% a m a a a .

... m a , \$ a ma m a a m a  
 a ma m a a a a ma a- a . D  
 C .D-19 a m a a ma m a m a ma ma a  
 a , a a a , a a a m a a a , a  
 a m a ma a m a 2020, \$ a m' m a  
 a a ▼ B35,873 m , a - - a 23.59%.

... a . . . a . . . a . . . a . . . m  
 D m m a a a m a a a . D  
 a m a a m a a a a a a a a  
 a a m . . . a ma a ma a a &D m ,  
 a a a m a a a a a &D a a  
 a a a a a a a a , a a a a &D a a  
 a ma a ma a . . . a ma a a a a , a a a  
 \$ a m, a a a \$ a m' a a a a a a a a  
 a a a ma a a .

... a a , a m m 4x a , a a m m  
 m m a a ma a a , a a a a a m a a m, a  
 m m m a a a m m a m a a ma . B ma  
 a a ma , a a a a a a a a ,  
 a a m , a a . D , a a ma a  
 &D a a ma a m a ma a a ma a m a m . A  
 a a a - a m a a a a a a . ma a m,  
 a m, a m a a a a a - a , a a

... m a a m , a m m -  
 m a , a m a , a m a a  
 a m .D , m m ma a m ma a m  
 a - a a a m a m . . . m a  
 m a m, m a a - a a , a a , m a a a a a  
 m , m a a a m , m m a  
 a a a m . a a a , a  
 a a a a a ma a , a m m a a m ,  
 a a a a a , m a a a a , a ma -  
 a a ma a m a a , a m m .



# Management

D a A a

(1) n

n

m C B

Items	Amount for the period	Amount for the corresponding period of last year	Period-on-period change (%)	Reasons
	13,965	14,085	0.85	
C a	6,216	5,599	11.02	
S a	3,931	4,998	21.35	1
A m a	1,322	1,148	15.16	
a a m	1,204	849	41.81	2
a	428	547	21.76	3
\ a a m a a	1,461	1,450	0.77	
\ a a m m a	-2,379	1,079	120.55	4
\ a a m a a	827	496	266.75	5

1: D ma m , a ma a a a a a m , a a am ma a (A a m a a a a (S ) a a ma ( a a ) a - - m a a ; a a

2: a , a a &D a ma a , ma m a a a m

3: - - a a ma - - a a a a a m a a m a

4: a - - a am a m a a a m

5: a a m a a a a a - m mm a a





# Management

D a A a

(1)

Table C

Principal operations by segments						
By segments	Revenue	Cost of sales	Gross profit margin (%)	Period-on-period change in revenue (%)	Period-on-period change in cost of sales (%)	Period-on-period change in gross margin
Media & Entertainment	9,952	3,754	62.28	7.97	3.79	4.27
Advertising	2,639	1,309	50.40	47.18	49.21	0.68
Other	1,359	1,130	16.82	6.85	4.68	9.16

Principal operations by products						
Products	Revenue	Cost of sales	Gross profit margin (%)	Period-on-period change in revenue (%)	Period-on-period change in cost of sales (%)	Period-on-period change in gross margin
Advertising	1,767	278	84.26	2.19	4.51	0.38
Media	422	119	71.89	59.94	71.10	1.83
Other	1,800	631	64.93	22.77	1.68	7.52
Media	755	48	93.63	38.35	16.94	1.64
Advertising	1,248	484	61.20	9.49	20.22	3.46
Other	247	20	91.74	41.03	0.42	3.37
Advertising	452	330	27.11	32.97	31.29	1.79

By geographical locations		Principal operations by geographical locations				Period-on-period	Period-on-period
		Revenue	Cost of sales	Gross profit margin (%)	Period-on-period change in revenue (%)	change in cost of sales (%)	change in gross margin
C	▼▼ <sup>a</sup> a	9,894	4,093	58.63	8.30	11.40	a 7.32
	a	4,071	2,123	47.84	23.53	10.29	a 6.26
	↑: .63						



(2) n 10% n ' n

l : m C : B

Name of investee	Nature of business	Principal activities	Registered capital	Total assets	Net assets	Revenue	Operating profit
S a m. a	a ma a m	a ma a m	100	307,273	84,008	203,765	4,808

(3) n n ( , n , n )

A	27 a 2020,	a a , a	a , a	a	a a m	a ,	a
		a a	50%	a a	a a	. A a	
		a a	100%	a a	a a		
8 A 2020,	a ma a .	a , a a ,	a s a a	A m	C C		
(B ), a	a ma a .	a a a	51%	C C a ma	a		
C C (B ). A a				100%			
C C a ma a .							

l : m C : B

Name of subsidiary	Acquired through	Net assets (as at the end of Reporting Period)	Net profit (from date of acquisition/ merger up to the end of Reporting Period)	Date of acquisition/ merger
a a	a	47	25	19 a 2020
C C a ma a	a	4	6	9 a 2020



... a m a r r a & a . . a r r a . . . .

... a 2020, a a a a a m , a a a

a &D a a a a a a a a , a a a a a a

m a a a a a a a , a a a m a a

a a a , a a a .

a a m a m a , m , a a ,

a m a m a a a , a m , a m a ( a a / ), A a m m a

a a a . ( C876, . . a - m a CD19 CA - ) a , m a a

' m a a a a a a ; a a a a a a a a

A a m a a a ( S ), a a a a a a a a C D-19 a

; a a a a m a a

a a a , D a a a a a a a a a a

a a a m a ; a a a 11 a a a a a a

a a m ( a a , a a a a m a , a

m a a a , a m a a , m m a a , a m a a , a a m a a

a , a a m a , a m a a , a m a , a a a ) a

m a a a a a , a a m a m a m a a a m

a a a m a m .

a 2020, a a a a , a a a a - a ,

a a m , a m a a a a , a a a a

a m m - , m - - - a , - - a , a a a a C (

a , a a a a ). a a a a a a a a

a a m a a . m , a a a

&D m a , m m m a a a a a a a

a a a a a a m -

- a a , a a &D a a a a a m .

a a a a a a m a a m a a a

a a a m m m C a a a , m a a a a m , a

m m m a m a m a a a a .

... a r r a . . a . . . . a r r a . . . .

... a 2020, a m &D, m a a a a a m a , a , a a m

m , a a a a a a a a m a a a , a a

a m a .

S a m a a a a a m a a a a a a a

m a a a , a m a a a a a m m a . S a m a

a a a a a a m m

a a a - a a a , a m a a m

, m a m . a a a m

a a a m a a a D a a a m , a a a a a a

a a a , a a a a a a a a a a

a , a a a a a a m a a

a m , a a a a m a a a a a a

m a a m a m a a a m a a , a

a a m a .

# Management

## D a A a

... a a a m  
a a a m a ma a a a m  
a m m a a a a am, a ma a  
a a , a a a a a  
a a m a

a a a S4  
... a 2020, m S a ' a m m m a  
a a a, a ma a a a m- a ma a m a a a a  
a a a a m a a m m a ma a a a m a m a -  
a (D ) a - a a a a ( B S). m a a m a a a ,  
a a a , a a , a ma a a a , a m a ma  
m , a a a a , a a a a a .  
m a m a a a a m , m a a a a  
a a a S a a a a a a C  
C m S a \* (重慶星榮整形醫院), m ' a C a \* (徐州婦兒醫院), S a a S a -  
C a \* (上海星晨兒童醫院) a , a m a a  
a a

a l a  
... a 2020, a a a a m S a m a ma a a  
m a , a a m a a a S a m a ma a a m a

a . a .  
... a 2020, a a a m a a a a , m  
a a a , a a a a m , a a a

### 3. Potential Risks

a a a a a m m  
a ma a m a a a a a C, a m  
a m , m a mm a a a a m a a , a , a  
a m a , a a a ma a , a a a  
m a ma a , m a a a m a , a ma a ma m  
a a , a a a ma , a a a ma m a  
a . m m a a m a a m a ma a a ,  
a m a , a a , ma m , m a a a ,  
a a , a m m a a a m , a m  
a a a C a a a a a a ma a , a  
a a a m .  
m m a , & D a a - m a a , a a m  
a a a a a m - a ma a ma a  
a . ma m a m a m a m .  
a a a a a m ma a , a m  
m a m a a m .



a a , a ma m a , a ma a m a  
, a m a a - .A a a a  
a , m a a m a a , a a  
m , m ma a m , a am a

ii. a .  
m m a m, S a a , ma - a a a  
ma a m m a a a m a ma a m a a ma  
.C m a m a ma m

a a , a a m a a am , a a m  
a a , a m m a a m a , a a  
a a m a ma a ma a m a ma a ma  
a a a m a a a ma a m , a  
m .  
m, ma a a ma a ma a  
a ma , a ma a a a , m m a  
a ma . a , C a' .C ( . a a C a m a a  
m a ma a ma ) a m a a a m a a  
a a a a , m a m a a ma . a m am a  
a a ma a m a a a , a a am m , a a a m m  
a a a ma a m a . a a a , ma a a ,  
a ma , a

a , a ma m a S a , m a a ,  
a a a a , a a m m a a a m  
a . a a a a a a a a m ma  
a A a, m a m a m a a m ,  
m , a a a m

a , a a m , a m a  
a a - , a a a a m m , m  
, a a &D a .A am m , a  
m m a , a a a a . ma , a a  
a ma m a a a , a a ma a .

iii. (1) &  
D m a m a a , a a, a a a a a a  
&D a ma a , a &D a a a m , ma ,  
, a .D &D a a a a , &D a  
ma ma ma , a a a  
m a a , a m a a a m ma  
a , a a a a m .  
a , m m a m a a , &D a a  
a a m m a m m &D , a  
m a am . a , a m  
a a a a a a a ,  
a a &D ma a ma a ma .







## RESULTS AND DIVIDENDS

As at the end of the reporting period, the Company's total assets were RMB41,777 million, an increase of RMB1,580,500 million from the end of the reporting period of the previous year. The Company's total liabilities were RMB17,011 million, an increase of RMB1,580,500 million from the end of the reporting period of the previous year. The Company's total equity was RMB24,766 million, an increase of RMB1,580,500 million from the end of the reporting period of the previous year.

## PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

### Sell back of "17 Fosun 01" Corporate Bond

On May 17, 2020, the Company redeemed RMB1,580,500,000 of the "17 Fosun 01" Corporate Bond (Face Value) (First Issue) (collectively referred to as "17 Fosun 01" Corporate Bond) issued by the Company in 2017. The Company received a total of RMB10,919,500,000 from the redemption of the "17 Fosun 01" Corporate Bond. The Company's total assets increased by RMB1,580,500 million, and the total liabilities increased by RMB1,580,500 million. The Company's total equity increased by RMB1,580,500 million. The Company's total assets, total liabilities, and total equity were RMB41,777 million, RMB17,011 million, and RMB24,766 million, respectively, as at the end of the reporting period.

## DIRECTORS

The Company's Board of Directors consists of the following members:

### Executive Directors

- Mr. Chen Qiyu (陳啟宇) (Chairman)
- Ms. Yao Fang (姚方) (Chairwoman)
- Ms. Wu Yifang (吳以芳) (Chairwoman)

### Non-executive Directors

- Mr. Xu Xiaoliang (徐曉亮)
- Mr. Gan Ping (龔平)
- Mr. Pan Donghui (潘東輝)

### Independent Non-executive Directors

- Ms. Jiang Hui (江蕙)
- Mr. Huang Tianyu (黃天祐)
- Ms. Li Ling (李玲)
- Mr. Tang Yuliang (湯谷良)

On May 17, 2020, the Company redeemed RMB1,580,500,000 of the "17 Fosun 01" Corporate Bond (Face Value) (First Issue) (collectively referred to as "17 Fosun 01" Corporate Bond) issued by the Company in 2017. The Company received a total of RMB10,919,500,000 from the redemption of the "17 Fosun 01" Corporate Bond. The Company's total assets increased by RMB1,580,500 million, and the total liabilities increased by RMB1,580,500 million. The Company's total equity increased by RMB1,580,500 million. The Company's total assets, total liabilities, and total equity were RMB41,777 million, RMB17,011 million, and RMB24,766 million, respectively, as at the end of the reporting period.



27 2019, a a 154,950 a 103 a a a a ma\$ a S m a  
 5,420 a a ma a , 102 a a a 154,650 a a ma a .  
 m a a ma a ma a a ma 1% a a  
 a a ma a a a a ma\$ a S m .

17 a 2020, a a ma m a a (1) a a a ma a  
 (10) a a ma a . A a a ma\$ a S m ,  
 m a a a ma, a m a ma a a m a m  
 a a ma a a a a a a a m a a ma  
 \$ a S m .

D : a a a a a a ma\$ a S m a

Participant	Date of Grant (dd-mm-yyyy)	Vesting Date (dd-mm-yyyy) <sup>(1)</sup>	Option share <sup>(1)</sup>	Exercise Period <sup>(1)</sup>	Outstanding options as at 1 January 2020	Adjusted during the Reporting Period <sup>(2)</sup>	Exercise price per share <sup>(3)</sup>	Forfeited or lapsed during the reporting period <sup>(4)</sup>	Outstanding options as at 30 June 2020
m	a a ma 27-6-2019	26-6-2020		26-6-2020 26-6-2029	151,350	1,362,150	542	(20,000)	1,493,500
		31-3-2021	40%	31-3-2021 26-6-2029					
		31-3-2022		31-3-2022 26-6-2029					
		31-3-2021	30%	31-3-2021 26-6-2029					
		31-3-2022		31-3-2022 26-6-2029					
		31-3-2022	30%	31-3-2022 26-6-2029					

- (1) a a ma a a a m a m m m a a a a  
 a a ma a a a a ma\$ a S m .
- (2) a m a a a a a a a a 17 a 2020.
- (3) a a a a a a a a a a 17 a 2020.
- (4) D a a ma a a 3 a a a a a m a a ma, a a 20,000 a
- (5) D a a a a a a ma\$ a S m .





## INTERESTS AND SHORT POSITIONS OF SUBSTANTIAL SHAREHOLDERS IN SHARES AND UNDERLYING SHARES

As at 30 June 2020, the following persons are known to have substantial interests in the shares and underlying shares of the Company, as defined in section 136 of the Companies Act, 2008. The interests are held in the shares and underlying shares of the Company as at 30 June 2020. The interests are held in the shares and underlying shares of the Company as at 30 June 2020.

Name of Shareholders	Nature of interest	Class of Shares	Number of Shares <sup>(1)</sup>	Approximate percentage of Shares in relevant class of Shares
	Ban	Share	48,803,000 ( ) <sup>(2)</sup>	8.84%
	Ban	Share	938,095,290 ( ) <sup>(2)</sup>	46.65%
	Ban	Share	48,803,000 ( ) <sup>(2)</sup>	8.84%
	Ban	Share	938,095,290 ( ) <sup>(2)</sup>	46.65%
	Ban	Share	48,803,000 ( ) <sup>(2)</sup>	8.84%
	Ban	Share	938,095,290 ( ) <sup>(2)</sup>	46.65%
	Ban	Share	48,803,000 ( ) <sup>(2)</sup>	8.84%
	Ban	Share	938,095,290 ( ) <sup>(2)</sup>	46.65%
	Ban	Share	48,803,000 ( ) <sup>(2)</sup>	8.84%
	Ban	Share	938,095,290 ( ) <sup>(2)</sup>	46.65%
	Ban	Share	114,075 ( )	0.01%
	Ban	Share	38,723,000 ( )	7.02%
	Ban	Share	38,707,016 ( )	7.01%
	Ban	Share	28,195,990 ( )	5.11%
			782,000 (S)	0.14%

(1) ( )

(1) ( ) ; (S) S

(2) Share 71.09%  
Share 85.29%

## DIRECTORS' AND SUPERVISORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

Directors and Supervisors have the right to acquire shares or debentures of the Company. The rights are held in the shares and debentures of the Company as at 30 June 2020.

# Statutory D

## MODEL CODE FOR SECURITIES TRANSACTIONS

C m a a a      ▼▼      C a a a m a      C a      a      a a .  
a ma      D , a D      m a a m      a a a      ▼▼  
C a      C      .

## COMPLIANCE WITH THE CG CODE

A a m a      a      S a a S      a a      S      a ,      C m a a ma  
m a      A      A a ,      a a a a a ,      S      S a a S  
a a      C m a m m      a m      a a      a , a  
m      a m a a m a      a      a      m      a      a      C m a .  
a      a a a a      C m a a a      a      C C .      C m a a  
m      a a a      a      C C      .

## REVIEW OF INTERIM RESULTS AND INTERIM REPORT BY THE AUDIT COMMITTEE

21 a a 2020.      a Ca      a a -      D a a m m      a m m      a m a . A  
m      ▼▼      B a , a m      ▼▼▼▼      a , a -      D , a a a      a m m      a  
m m      B a a a .

30 2020.      a      a a -      D a a m m      a m m      a m  
a a m . A      m      B a , a m      ▼▼ .      , a -      D , a a  
a a m m      a m m      B a a a .

A a      , a m m      C m a m      ▼▼ . a a ( a ma ), a      -  
D      ▼▼ . a a , a      -      D , a ▼▼ .      , a -      D .  
ma      a m m      a      a m      a a      ,      m a a m a      a  
m      C m a , a      m m      a a a      B a .

a m m      C m a a      a      m      a      m      m

30 2020.  
B a      B a  
Chen Qiyu  
n

S a a ,      C  
25 A      2020

# Interim Condensed Consolidated

S a m




For the six months ended 30 June 2020

		For the six months ended 30 June	
		2020 RMB'000 (Unaudited)	2019 B'000 ( )
<b>REVENUE</b>	5	13,965,179	14,085,146
C a		(6,215,872)	(5,598,983)
		7,749,307	8,486,163
m	6	180,429	109,724
S a		(3,931,067)	(4,998,448)
A m a		(1,322,239)	(1,147,889)
a a m		(1,204,425)	(849,383)
.m a m a a a		(42,765)	(21,918)
a	7	603,622	389,686
		(52,138)	(45,617)
m		96,436	86,650
a	8	(427,878)	(546,940)
S a a :		(46,558)	(25,933)
A a		698,964	760,055
<b>PROFIT BEFORE TAX</b>	9	2,301,688	2,196,150
m a	10	(392,081)	(376,521)
<b>PROFIT FOR THE PERIOD</b>		1,909,607	1,819,629
A a :		1,714,710	1,516,120
- a		194,897	303,509
		1,909,607	1,819,629
<b>EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT</b>	12	RMB0.67 Yuan	B0.59 /a
Ba			
D		RMB0.67 Yuan	B0.59 /a



# Interim Condensed Consolidated



30 June 2020

		30 June 2020 RMB'000 (Unaudited)	31 Dec 2019 B'000 (A)
<b>NON-CURRENT ASSETS</b>			
Property, plant and equipment	13	11,313,846	10,720,960
Intangible assets		2,389,837	2,454,742
Financial assets at fair value through profit or loss		9,093,050	9,013,990
Financial assets at fair value through other comprehensive income		9,238,300	9,036,246
Prepaid expenses and deposits		356,204	381,332
Other non-current assets		21,712,444	20,491,557
Deferred tax assets		60,945	107,709
Other non-current assets		1,851,891	1,983,155
Derivative financial instruments		236,457	196,095
		1,300,703	1,273,605
		<b>57,553,677</b>	<b>55,659,391</b>
<b>CURRENT ASSETS</b>			
Financial assets at fair value through profit or loss	14	4,561,539	3,940,537
Financial assets at fair value through other comprehensive income		5,271,488	4,607,722
Prepaid expenses and deposits		1,628,029	1,420,087
Other current assets		992,812	456,651
Derivative financial instruments		354,915	445,103
Current tax assets		9,750,416	9,533,268
		<b>22,559,199</b>	<b>20,403,368</b>
<b>CURRENT LIABILITIES</b>			
Financial liabilities at fair value through profit or loss	15	2,864,017	2,397,315
Financial liabilities at fair value through other comprehensive income		6,116,649	5,376,193
Other current liabilities	16	12,404,601	8,560,202
Derivative financial instruments		138,571	143,786
Current tax liabilities		527,652	503,683
Other current liabilities		487,052	452,587
		<b>22,538,542</b>	<b>17,433,766</b>
<b>NET CURRENT ASSETS</b>		<b>20,657</b>	<b>2,969,602</b>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		<b>57,574,334</b>	<b>58,628,993</b>



# Interim Condensed Consolidated

## S a m C a

For the six months ended 30 June 2020

### Attributable to owners of the parent

	Share capital RMB'000	Share premium RMB'000	Fair value reserve RMB'000	Statutory surplus reserve RMB'000	Other reserve RMB'000	Exchange fluctuation reserve RMB'000	Retained profits RMB'000	Total RMB'000	Non-controlling interests RMB'000	Total equity RMB'000
A 1 a a 2020 (A )	2,562,899	11,385,162*	(35,546)*	2,523,799*	899,356*	(420,878)*	14,916,387*	31,831,179	7,316,147	39,147,326
✓ m ✓ :	—	—	—	—	—	—	1,714,710	1,714,710	194,897	1,909,607
C a a a a a m ,	—	—	3,819	—	—	—	—	3,819	(68)	3,751
S a m m	—	—	96,891	—	—	—	—	96,891	—	96,891
a a a a	—	—	—	—	—	(154,873)	—	(154,873)	(100,736)	(255,609)
a m m	—	—	100,710	—	—	(154,873)	1,714,710	1,660,547	94,093	1,754,640
A -	—	—	—	—	159,607	—	—	159,607	(521,291)	(361,684)
D m a a a	—	—	—	—	(784)	—	—	(784)	62	(722)
D a a a	—	—	—	—	(2,433)	—	—	(2,433)	—	(2,433)
C a a m -	—	—	—	—	—	—	—	—	56	56
D a a -	—	—	—	—	—	—	—	—	24,495	24,495
D a a -	—	—	—	—	—	—	—	—	(241,721)	(241,721)
- a - a a m	—	—	—	—	—	—	—	—	162,645	162,645
a a a m a a	—	—	—	—	5,346	—	—	5,346	(18,356)	(13,010)
S a a a	—	—	—	—	329,734	—	—	329,734	—	329,734
a 2019 a	—	—	—	—	—	—	(1,000,505)	(1,000,505)	—	(1,000,505)
( 11)	—	—	—	—	—	—	—	—	—	—
a a a m a a	—	—	107,320	—	—	—	(107,320)	—	—	—
A 30 2020 (A )	2,562,899	11,385,162*	172,484*	2,523,799*	1,390,826*	(575,751)*	15,523,272*	32,982,691	6,816,130	39,798,821

\* a a m a B30,419,792,000 (31 D m 2019: B29,268,280,000) a a m





# Interim Condensed Consolidated

S a m

Ca

For the six months ended 30 June 2020

		For the six months ended 30 June	
		2020	2019
		RMB'000	B'000
		(Unaudited)	(Unaudited)
Cash and cash equivalents		1,928,625	1,849,335
Less: Cash equivalents		(467,328)	(399,147)
<b>Net cash and cash equivalents</b>		<b>1,461,297</b>	<b>1,450,188</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>			
✓	Acquisition of subsidiaries, net of cash acquired	(1,904,148)	(2,040,985)
A	Acquisition of subsidiaries, net of cash acquired	(8,400)	(133,162)
✓	Acquisition of subsidiaries, net of cash acquired	(192,431)	(174,524)
✓	Acquisition of subsidiaries, net of cash acquired	(435,607)	(109,283)
D	Acquisition of subsidiaries, net of cash acquired	151,917	35,418
D	Acquisition of subsidiaries, net of cash acquired	474,449	642,245
D	Acquisition of subsidiaries, net of cash acquired	—	2,296
D	Acquisition of subsidiaries, net of cash acquired	67,961	41,866
D	Acquisition of subsidiaries, net of cash acquired	—	1,039
D	Acquisition of subsidiaries, net of cash acquired	18,718	20,053
D	Acquisition of subsidiaries, net of cash acquired	—	—
	Acquisition of subsidiaries, net of cash acquired	1,708	—
✓	Acquisition of subsidiaries, net of cash acquired	5,439	26,015
✓	Acquisition of subsidiaries, net of cash acquired	50,228	—
(	Acquisition of subsidiaries, net of cash acquired	(570,138)	570,562
	Acquisition of subsidiaries, net of cash acquired	(38,629)	39,801
<b>Net cash used in investing activities</b>		<b>(2,378,933)</b>	<b>(1,078,659)</b>

# Interim Condensed Consolidated

S a m C a

m 30 2020





4. OPERATING SEGMENT INFORMATION

	2020	2019
Operating segments	1	1
(a) Segment revenue	1,234,567	1,123,456
(b) Segment profit	123,456	112,345
(c) Segment assets	1,234,567	1,123,456
(d) Segment liabilities	123,456	112,345
(e) Segment capital expenditure	123,456	112,345
(f) Segment depreciation and amortisation	123,456	112,345
(g) Segment research and development	123,456	112,345
(h) Segment employee headcount	1,234	1,123
(i) Segment revenue by geographical area		
(j) Segment profit by geographical area		
(k) Segment assets by geographical area		
(l) Segment liabilities by geographical area		
(m) Segment capital expenditure by geographical area		
(n) Segment depreciation and amortisation by geographical area		
(o) Segment research and development by geographical area		
(p) Segment employee headcount by geographical area		

# Notes to Interim Condensed Consolidated

a a s a m

30 2020

## 4. OPERATING SEGMENT INFORMATION (Continued)

Six months ended 30 June 2020 (unaudited)

	Pharmaceutical manufacturing and R&D RMB'000	Medical devices and medical diagnosis RMB'000	Healthcare Service RMB'000	Pharmaceutical distribution and retail RMB'000	Other business operations RMB'000	Adjustments and Eliminations RMB'000	Total RMB'000
<b>Segment revenue:</b>							
Sale of pharmaceutical products	9,952,096	2,638,887	1,359,017	—	15,179	—	13,965,179
License fee	48,294	46,610	4,700	—	8,270	(107,874)	—
<b>Total</b>	<b>10,000,390</b>	<b>2,685,497</b>	<b>1,363,717</b>	<b>—</b>	<b>23,449</b>	<b>(107,874)</b>	<b>13,965,179</b>
<b>Segment results*</b>							
Cost of sales	1,115,513	509,746	31,373	—	(4,289)	(19,026)	1,633,317
Depreciation and amortization	135,673	10,551	16,910	—	16,579	—	179,713
Administrative expenses	157,704	14,210	3,393	—	275,233	30	450,570
Research and development expenses	56,129	10,345	17,531	—	185	(5,291)	78,899
Impairment losses	(51,353)	(14,125)	(17,409)	—	(5,587)	26,170	(62,304)
Other non-recurring gains	27,605	(55,433)	(6,267)	—	(22,062)	—	(56,157)
Share of profit of associates	(45,744)	—	—	—	(814)	—	(46,558)
Share of loss of associates	32,681	24,021	(31,134)	724,041	(50,645)	—	698,964
Financial income							171,305
Financial expense							(365,574)
Income tax expense							(380,487)
<b>Total</b>	<b>1,428,208</b>	<b>499,315</b>	<b>14,397</b>	<b>724,041</b>	<b>208,600</b>	<b>1,883</b>	<b>2,301,688</b>
Other income	(313,433)	(65,625)	(12,784)	—	(239)	—	(392,081)
<b>Total</b>	<b>1,114,775</b>	<b>433,690</b>	<b>1,613</b>	<b>724,041</b>	<b>208,361</b>	<b>1,883</b>	<b>1,909,607</b>
<b>Segment assets:</b>							
Property, plant and equipment	41,047,332	8,262,367	9,812,781	13,877,770	4,251,314	(1,683,155)	75,568,409
Intangible assets	349,474	—	—	—	6,730	—	356,204
Other assets	2,248,581	1,102,609	1,624,283	13,877,770	2,859,201	—	21,712,444
Goodwill							4,544,467
<b>Total</b>							<b>80,112,876</b>
<b>Segment liabilities:</b>							
Accounts payable	18,654,179	1,937,780	2,229,824	—	386,141	(9,370,028)	13,837,896
Other liabilities							26,476,159
<b>Total</b>							<b>40,314,055</b>
<b>Other segment information:</b>							
Depreciation and amortization	590,999	96,170	133,901	—	15,197	—	836,267
Impairment losses	(32,251)	49,686	2,365	—	22,048	—	41,848
Capital expenditure**	1,309,447	97,984	356,886	—	47,953	—	1,812,270

\* Segment results are presented on a cost of sales basis. Other segment results are presented on a gross profit basis.

\*\* Capital expenditure includes the purchase of property, plant and equipment, intangible assets, and other assets.

# Notes to Interim Condensed Consolidated

a a s a m

30 June 2020

## 4. OPERATING SEGMENT INFORMATION (Continued)

### Six months ended 30 June 2019 (unaudited)

	2019 \$ million	2019 \$ million	2019 \$ million	2019 \$ million	2019 \$ million	2019 \$ million
<b>Segment revenue:</b>						
Segment revenue	10,814,123	1,792,865	1,458,512		19,646	14,085,146
Cost of sales	8,421	19,401	1,876		20,674	(50,372)
<b>Segment results*</b>						
Segment revenue	1,204,721	291,795	168,982		10,328	1,655,939
Cost of sales	75,540	13,034	3,681		3,326	95,581
Other operating expenses	281,499	(3,481)	(748)	7,274	2,679	287,223
Depreciation and amortisation	50,628	16,153	21,874		216	87,635
Finance costs	(56,712)	(9,467)	(12,032)		(6,320)	(55,429)
Share of results of associates	(15,616)	(22,095)	(15,446)		1,121	(52,036)
Share of results of joint ventures	(25,565)	477			(845)	(25,933)
Other income	37,529	(25,330)	(13,655)	774,939	(13,428)	760,055
Other operating expenses						115,621
Depreciation and amortisation						(491,511)
Finance costs						(180,995)
Share of results of associates	1,552,024	261,086	152,656	782,213	(2,923)	2,196,150
Share of results of joint ventures	(319,655)	(30,673)	(51,774)		(258)	(402,360)
Other operating expenses						25,839
Other income	1,232,369	230,413	100,882	782,213	(3,181)	1,819,629
<b>Segment assets:</b>						
Segment assets	36,425,494	6,874,258	10,781,464	12,429,996	4,362,843	69,383,471
Goodwill	399,018	12,808			9,134	420,960
Intangible assets	2,153,707	948,143	3,232,275	12,429,996	3,085,411	21,849,532
Property, plant and equipment						4,249,250
Other non-current assets						73,632,721
<b>Segment liabilities:</b>						
Segment liabilities	15,346,659	1,505,277	1,698,142		281,002	10,240,804
Other liabilities						28,931,431
Other non-current liabilities						39,172,235
<b>Other segment information:</b>						
Depreciation and amortisation	502,504	85,220	133,338		19,190	740,252
Finance costs	2,435	19,425	6,493		(2,198)	26,155
Capital expenditure**	1,016,436	85,165	160,766		95,489	1,357,856

\* Segment results are presented on a cost of sales basis. Other operating expenses include depreciation and amortisation, finance costs, share of results of associates and joint ventures, and other income.

\*\* Capital expenditure includes the purchase of property, plant and equipment, intangible assets, and other non-current assets.

# Notes to Interim Condensed Consolidated

Financial Statements

30 June 2020

## 5. REVENUE

Revenue is derived from:

	For the six months ended 30 June	
	2020 RMB'000 (Unaudited)	2019 RMB'000 (Audited)
Revenue from contracts with customers	13,951,418	14,066,560
Revenue from other contracts	13,761	18,586
<b>Total revenue</b>	<b>13,965,179</b>	<b>14,085,146</b>



# Notes to Interim Condensed Consolidated

a a s a m

30 June 2020

## 5. REVENUE (Continued)

For the six months ended 30 June 2019 (unaudited)

	2019 Revenue &D B'000	2019 Revenue B'000	2019 Revenue B'000	2019 Revenue B'000	2019 Revenue B'000
<b>Types of goods or services</b>					
Software	10,564,090	1,671,542	27,181		12,262,813
Services	238,771	111,402	1,430,327	2,144	1,782,644
Software & services	11,182	9,921			21,103
<b>Total</b>	<b>10,814,043</b>	<b>1,792,865</b>	<b>1,457,508</b>	<b>2,144</b>	<b>14,066,560</b>
<b>Geographical markets</b>					
North America	8,288,825	1,024,242	1,457,508	406	10,770,981
Europe	2,525,218	768,623		1,738	3,295,579
<b>Total</b>	<b>10,814,043</b>	<b>1,792,865</b>	<b>1,457,508</b>	<b>2,144</b>	<b>14,066,560</b>
<b>Timing of revenue recognition</b>					
Software	10,575,272	1,681,463	27,181		12,283,916
Services	128,209	41,595	1,430,327	2,144	1,602,275
Software & services	110,562	69,807			180,369
<b>Total</b>	<b>10,814,043</b>	<b>1,792,865</b>	<b>1,457,508</b>	<b>2,144</b>	<b>14,066,560</b>

# Notes to Interim Condensed Consolidated

Financial Statements

30 June 2020

## 6. OTHER INCOME

	For the six months ended 30 June	
	2020 RMB'000 (Unaudited)	2019 RMB'000 (Unaudited)
Dividend income	20,391	17,523
Interest income	158,367	92,104
Other income	1,671	97
	<b>180,429</b>	<b>109,724</b>

## 7. OTHER GAINS

	For the six months ended 30 June	
	2020 RMB'000 (Unaudited)	2019 RMB'000 (Unaudited)
Gain on disposal of subsidiaries	87,209	27,528
Gain on disposal of investments	439,102	327,405
Gain on disposal of property, plant and equipment	—	2,186
Other gains	77,311	32,567
	<b>603,622</b>	<b>389,686</b>

## 8. FINANCE COSTS

	For the six months ended 30 June	
	2020 RMB'000 (Unaudited)	2019 RMB'000 (Unaudited)
Interest expense	425,687	543,161
Interest income	12,188	12,355
Other finance costs	(9,997)	(8,576)
	<b>427,878</b>	<b>546,940</b>



# Notes to Interim Condensed Consolidated

Financial Statements

30 June 2020

## 10. INCOME TAX

The Company is subject to corporate income tax at a rate of 25% (2019: 25%) on its taxable income. The Company is also subject to a withholding tax rate of 10% on dividends distributed to foreign investors. The Company is also subject to a withholding tax rate of 20% on interest income received from financial institutions.

The Company is also subject to a withholding tax rate of 16.5% on interest income received from financial institutions. The Company is also subject to a withholding tax rate of 9.48% on interest income received from financial institutions. The Company is also subject to a withholding tax rate of 34.94% on interest income received from financial institutions. The Company is also subject to a withholding tax rate of 25.17% on interest income received from financial institutions. The Company is also subject to a withholding tax rate of 31% on interest income received from financial institutions. The Company is also subject to a withholding tax rate of 22% on interest income received from financial institutions. The Company is also subject to a withholding tax rate of 33.33% on interest income received from financial institutions.

For the six months ended 30 June 2020 compared to 30 June 2019:

	For the six months ended 30 June	
	2020	2019
	RMB'000	US\$'000
	(Unaudited)	(Unaudited)
Income tax expense	467,327	464,045
Income tax credit	(75,246)	(87,524)
<b>Income tax expense</b>	<b>392,081</b>	<b>376,521</b>

## 11. DIVIDENDS

The Company has not declared any dividends for the six months ended 30 June 2020 (2019: nil).

The Company has not declared any dividends for the six months ended 30 June 2020 (2019: nil).





# Notes to Interim Condensed Consolidated

a a s a m

30 June 2020

## 14. TRADE AND BILLS RECEIVABLES (Continued)

	30 June 2020 RMB'000 (Unaudited)	31 D m 2019 B'000 (A )
1 a	4,999,855	4,302,722
1 2 a	144,630	111,346
2 3 a	67,601	61,584
3 a	125,446	114,549
	5,337,532	4,590,201
	(256,987)	(222,601)
	5,080,545	4,367,600

A a 30 2020, a a a a ▼▼ B5,300,000 (2019: ▼▼ B8,146,000)

## 15. TRADE AND BILLS PAYABLES

	30 June 2020 RMB'000 (Unaudited)	31 D m 2019 B'000 (A )
a a a	2,566,965	2,152,747
B a a	297,052	244,568
	2,864,017	2,397,315

a a a a a - - a a a ma a -m m.

	30 June 2020 RMB'000 (Unaudited)	31 D m 2019 B'000 (A )
1 a	2,516,937	2,105,194
1 2 a	34,054	36,473
2 3 a	9,155	3,082
3 a	6,819	7,998
	2,566,965	2,152,747











# Notes to Interim Condensed Consolidated

Financial Statements

30 June 2020

## 19. RELATED PARTY TRANSACTIONS

### (a) Sales of pharmaceutical products and services

	For the six months ended 30 June	
	2020	2019
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Sichuan Amoyang Pharmaceutical Co., Ltd. (4 & 6 & 15)	1,395,932	1,567,956
Chongqing Amoyang Pharmaceutical Co., Ltd. (1 & 4 & 16)	188,335	205,246
Chongqing Amoyang Pharmaceutical Co., Ltd. (3 & 4 & 10 & 16)	98,576	216
Chongqing Amoyang Pharmaceutical Co., Ltd. (1 & 4)	92,686	49,757
Chongqing Amoyang Pharmaceutical Co., Ltd. (1 & 4)	68,855	42,836
Chongqing Amoyang Pharmaceutical Co., Ltd. (4 & )	7,036	32,492
Chongqing Amoyang Pharmaceutical Co., Ltd. (4 & )	4,315	
Chongqing Amoyang Pharmaceutical Co., Ltd. (1 & 4)	4,030	3,256
Chongqing Amoyang Pharmaceutical Co., Ltd. (1 & 4)	2,555	1,453
Chongqing Amoyang Pharmaceutical Co., Ltd. (1 & 4)	1,777	22
Chongqing Amoyang Pharmaceutical Co., Ltd. (2 & 4 & 17)	1,612	4,702
Chongqing Amoyang Pharmaceutical Co., Ltd. (1 & 4)	1,262	
Chongqing Amoyang Pharmaceutical Co., Ltd. (1 & 4 & 6)	737	1,575
Chongqing Amoyang Pharmaceutical Co., Ltd. (2 & 4)	406	148
Chongqing Amoyang Pharmaceutical Co., Ltd. (4 & )	42	
Chongqing Amoyang Pharmaceutical Co., Ltd. (4 & )	16	
Chongqing Amoyang Pharmaceutical Co., Ltd. (4 & 7)	16	17
Chongqing Amoyang Pharmaceutical Co., Ltd. (2 & 4)	14	12
Chongqing Amoyang Pharmaceutical Co., Ltd. (1 & 4)	13	60
Chongqing Amoyang Pharmaceutical Co., Ltd. (1 & 4)	3	
Chongqing Amoyang Pharmaceutical Co., Ltd. (1 & 4)	—	17
Chongqing Amoyang Pharmaceutical Co., Ltd. (1 & 4)	—	1
	<b>1,868,218</b>	<b>1,909,766</b>

# Notes to Interim Condensed Consolidated

a a s a m

30 June 2020

## 19. RELATED PARTY TRANSACTIONS (Continued)

### (b) Purchase of pharmaceutical products and services

	Six months ended 30 June	
	2020 RMB'000 (Unaudited)	2019 B'000 ( )
Siam C., .a a ( 4 & 6 & 15)	128,644	125,937
. a a m a a ( 3 & 4 & 11 & 16)	96,578	1,156
a C m a a .( 4 & )	87,769	8,899
C. a m a a C., .a a ( 1 & 4 & 16)	2,266	410
A a a s & C., .( 1 & 4)	1,071	1,164
A s a m a a C., .( 1 & 4)	1,007	2,126
S a a a a D m C., .( 2 & 4 & 17)	907	85
a D'a D a C., .a a ( 4 & )	510	3,352
L a a a ., .( 4 & )	33	
S a a a a m a C., .( 1 & 4)	23	
S a a a B m a ., .( 1 & 4)	—	1,318
C C (s ) a m a a C., .( 1 & 4 & 1 )	—	1,228
	<b>318,808</b>	<b>145,675</b>

### (c) Leasing and property management services

As lessor	Six months ended 30 June	
	2020 RMB'000 (Unaudited)	2019 B'000 ( )
B a a C., .( 2 & 5)	6,106	5,310
. a a m a a ( 3 & 5 & 12 & 16)	3,529	7,895
S a a m a m a C., .( 1 & 5)	733	
S a a a a D m C., .( 2 & 5 & 17)	578	325
D . m a a a m (s a a) C., .( 5 & 7)	471	454
a a C a a a a ( 1 & 5 & 6)	413	131
S a a a a a m a s a a D m . ( 2 & 5)	216	
. S a a a (s a a) C., .( 1 & 5)	145	86
S a a C a a a ( 1 & 5)	65	
S a a m a C., .( 1 & 5)	—	264
	<b>12,256</b>	<b>14,465</b>

# Notes to Interim Condensed Consolidated

a a s a m

30 2020

## 19. RELATED PARTY TRANSACTIONS (Continued)

### (c) Leasing and property management services (Continued)

	Six months ended 30 June	
	2020 RMB'000 (Unaudited)	2019 B'000 ( )
<b>As lessee</b>		
... a a m a a ( 3 & 5 & 13 & 16)	2,952	5,477
D a a a a a ( 5 & )	117	114
S a a a a ( 5 & )	43	41
S a a B a C ., ( 5 & )	—	2,500
	<b>3,112</b>	<b>8,132</b>

	Six months ended 30 June	
	2020 RMB'000 (Unaudited)	2019 B'000 ( )
<b>Property management services</b>		
... a a m a a ( 3 & 5 & 14 & 16)	6,904	6,651

### (d) Loans from/to a related parties

C m a a a a m a C a m ( a ),  
 a a a a a C m a a a ,  
 , m a a a a C a B a a C m m a m  
 1 a a 2020 a 31 D m 2022. m a m m a a a a  
 a B1,000,000,000. m a m m a a a a a  
 B1,000,000,000.

	Six months ended 30 June	
	2020 RMB'000 (Unaudited)	2019 B'000 ( )
<b>Maximum daily outstanding balance of deposits in Fosun Finance</b>		
a C a m ( & 16)	979,619	574,422







# Notes to Interim Condensed Consolidated

Financial Statements

30 June 2020

## 19. RELATED PARTY TRANSACTIONS (Continued)

### (e) Interest income from/to related parties (Continued)

- (Continued)
- (14) During the period, the Group has entered into various financial arrangements with related parties, including the following:
- (15) The Group has provided loans to related parties, including the following:
- (16) The Group has provided financial guarantees to related parties, including the following:
- (17) The Group has provided financial assistance to related parties, including the following:
- (18) The Group has provided financial assistance to related parties, including the following:

### (f) Compensation of key management personnel of the Group

	Six months ended 30 June	
	2020 RMB'000 (Unaudited)	2019 RMB'000 (Audited)
Key management personnel	50,051	25,416
Senior management	15,410	12,417
Other key management personnel	243	501
<b>Total</b>	<b>65,704</b>	<b>38,334</b>

### (g) Outstanding balances with related parties

- (1) As at 30 June 2020, the Group has outstanding balances with related parties of RMB51,513,000 (31 December 2019: RMB4,030,000).
- (2) As at 30 June 2020, the Group has outstanding balances with related parties of RMB983,814,000 (31 December 2019: RMB1,071,384,000).
- (3) As at 30 June 2020, the Group has outstanding balances with related parties of RMB193,654,000 (31 December 2019: RMB212,705,000).
- (4) As at 30 June 2020, the Group has outstanding balances with related parties of RMB3,942,000 (31 December 2019: RMB5,526,000).
- (5) As at 30 June 2020, the Group has outstanding balances with related parties of RMB118,211,000 (31 December 2019: RMB46,027,000).

# Notes to Interim Condensed Consolidated

Financial Statements

30 June 2020

## 19. RELATED PARTY TRANSACTIONS (Continued)

### (g) Outstanding balances with related parties (Continued)

As at 30 June 2020, the following amounts were due from related parties: ▼▼ B81,705,000

20. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Table with 2 columns: Description of financial instruments and Fair value at 30 June 2020. The table contains detailed information about various financial instruments, including their classification and valuation methods.

Unobservable inputs for Level 3 assets

Table with 2 columns: Description of Level 3 assets and Fair value at 30 June 2020. This table provides details on assets whose fair value is determined using unobservable inputs, including the valuation techniques used.



# Notes to Interim Condensed Consolidated

a a s a m

30 June 2020

## 20. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

### Fair value hierarchy (Continued)

	Financial assets at fair value through profit and loss RMB'000 (Unaudited)	Equity investments Designated at fair value through other comprehensive income RMB'000 (Unaudited)
At 1 July 2020	1,825,724	53,246
Acquisitions	118,774	—
Disposals	—	6,284
At 30 June 2020	1,694,007	59,530
At 1 July 2019	2,155,293	82,301
Acquisitions	231,452	—
Disposals	—	(29,271)
At 30 June 2019	1,786,569	52,690

# Notes to Interim Condensed Consolidated

Financial Statements

30 2020

## 20. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

### Fair value hierarchy (Continued)

As at 30 June 2020 (RMB'000)

	Fair value measurement using			Total RMB'000
	Quoted prices in active markets (Level 1) RMB'000	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	
Am - ma	—	—	2,643,984	2,643,984

As at 31 December 2019 (RMB'000)

	Fair value measurement using			Total RMB'000
	Quoted prices in active markets (Level 1) RMB'000	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	
Am			209,286	209,286
Am - ma			2,608,958	2,608,958
			2,818,244	2,818,244

As at 30 June 2019 (RMB'000)

	Six months ended 30 June	
	2020 RMB'000 (Unaudited)	2019 RMB'000 (Audited)
Am - ma	2,818,244	2,913,876
Am	35,026	46,708
Am - ma	(209,286)	
Am - ma	2,643,984	2,960,584

As at 30 June 2020, the fair value of the financial instruments is measured at the end of the reporting period.

# Notes to Interim Condensed Consolidated

a a s a m

30 June 2020

## 21. CONTINGENT LIABILITIES

A a 30 2020 a 31 D m 2019, a a a .

## 22. EVENTS AFTER THE REPORTING PERIOD

A a a a , a a a .

## 23. APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

m a a a a m a a a a D 25 A  
2020.

m , , m a a m a .

AS a ( ) m a ( ) C m a a m a a B1.00 a , a  
 S a a S a a a B

AS a ( ) ( ) AS a

A a a A a m C m a

A A A a a a C m a

A a a m a C , . \* (錦州奧鴻藥業有限責任公司), a a C m a

A a a C m m a A a a

B a a D

B a a B a

B a B a a AB, a m a S , a a a C m a

BS B S m , a . a a a m a

CA A C A & A

C C C a a C a C a a a A 14

C C a a a

C a a a C a C a a C m a m \* (佛山市禪城區中心醫院有限公司), a -  
 m a a a a a D  
 A m a C a D , a (佛山市禪城區人口和衛生藥品監督管理局), a  
 a C m a

C a a a C a a a m C m a m \* (佛山市禪怡健康管理有限公司)

C C (B ) C C a m a a D m (B ) C , . \* (希米科醫藥技術發展(北京)有限  
 公司)

C C a m a a C C (S ) a m a a C , . \* (希米科(蘇州)醫藥科技有限公司) ( a  
 A (S ) a m a a C , . \* (復星艾迪(蘇州)醫藥科技有限  
 公司)), a a C m a a a

C m a a m a a ( ) C , . \* (上海復星醫藥(集團)股份有限公司), a  
 m a a C m a , S a a AS a a a  
 a a a B a S a a S a a S a a ,

a ( ) a m a a a C m a ,  
 m a a a a , a , a a ,  
 a a a



C5 C

C a S a C mm \* (中國證券監督管理委員會), a a  
a a C a a ma

D ( )

( ) C m a

B DA

a , a , a a am a

S

m , S a a a

S C mm

m a , S a a a C mm C m a

L

a L

S a a ( ) C m a m \* (上海復星高科技(集團)有限公司), a  
C m a . a a a a a a  
14A.07(1)

m (復星控股有限公司), a

a a a a a C m a

a a

a a m (復星國際有限公司), a a a a  
a a a C m a , S  
a (S C : 00656)

a a

a a m (復星國際控股有限公司), a 85.29% a

# Definitions

a	a	a	a	a C m a m * (岳陽廣濟醫院有限公司), a a C m a
➤ a m a	➤ a m a	➤ a m a C m a m * (桂林南藥股份有限公司), a a C m a		
§ a ( )	a a a a C m a , a m a a	B1.00 a , a	§ a a a	
§ a ( )	( ) § a			
a C a a a	a C a a a			
a	§ a * (深圳恒生醫院), a a C m a			
§	a a § a a			
	§ a A m a ➤ C			
a \$	a			
§ a	§ a m			
a' a a a	a' a a a a C . , * (淮安興淮國際醫院有限公司), a a C m a			
	§ a - a ( § a a ) C . , * (直觀復星醫療器械技術(上海)有限公司) a . § a - ( ) C . , * (直觀復星(香港)有限公司)			
↘	, a a . a			
a a	a a			
m a	A m C a a * (安徽濟民腫瘤醫院), a a - (民辦非企業單位) a ➤ C, a a C m a			
▼▼ C	▼▼ C § a a D . A 10			
↘A▼	↘a a A a a a▼ a .			
▼▼A	↘a a▼ a ➤ A m a * (中華人民共和國國家藥品監督管理局), ➤ C m a a			
↘S	↘a a S a . a m , a . a a a ▼ m a			
§	§ a			
➤C	➤C a a a			

✓  
 ✓ a  
 ✓ C C a  
 ✓ C a a a  
 ✓ a a  
 &D  
 a a m  
 6-m m 1 a a 2020 30 2020  
 ▼▼ B  
 S C  
 S a  
 S m a (C a 571 a), a am  
 S a a B, .\*(上海復宏漢霖生物技術股份有限公司), a m a  
 S a a (\$ :02696) a a a C m a  
 S a a B a ma a S a a B a ma a C ., .\*(上海復宏漢霖生物製藥有限公司), a a  
 C m a  
 S a a S a a S a a \* (《上海證券交易所股票上市規則》)  
 S a a S a a S a a \* (上海證券交易所)  
 a ▼▼ a S a a a ▼▼ a D m C ., .\*(上海星耀醫學科技發展有限公司),  
 a a C m a a a  
 S a S a  
 S a a a a C m a a m a a ▼▼ B1.00 a, m A  
 S a a S a  
 S S a a \* (深圳證券交易所)  
 S a m S a m C . .\*(國藥控股股份有限公司), a m a S  
 a ( :01099)  
 S a m. a S a m. a. m C ., .\*(國藥產業投資有限公司)  
 S am ▼▼ a S am ▼▼ a, a m a S a a (\$ :01696) a a  
 a a a a ( ) a m a  
 S m m S C mm

# Definitions

S C mm S C mm C m a  
 S a a / S a Ca a S a a C ., .\* (宿遷市鐘吾醫院有限責任公司) S a Ca a \* (宿遷市腫瘤醫院), a a C m a  
 S a a a a S a a a a a am a C m a m \* (宿遷市新星康復體檢有限公司), a a C m a  
 S. S a S a Am a, a , a S a S a a D C m a S a a  
 S a , S D S \$ S a S a  
 S a S a  
 S. DA S. a D A m a  
 a a a ma a a a B a ma a C m a m \* (江蘇萬邦生化醫藥集團有限責任公司), a a C m a  
 a a a a m C m a \* (溫州老年病醫院有限公司), a a C m a  
 a a a a a a  
 a a a C ., .\* (武漢濟和醫院有限公司), a a C m a  
 C S a a D / a m C m a \* (《董事有關僱員進行證券交易的書面指引》)  
 a a ma a C m a m \* (重慶藥友製藥有限責任公司), a a C m a  
 a C a a a C a a m \* (珠海禪誠醫院有限公司), a a C m a  
 %  
 , a a C am , a , a a , a C a a a a , C a a .